From: A review on the role of MEG8 lncRNA in human disorders
Tumor/ disorder type | Targets/ Regulators and Signaling Pathways | Cell line | Function | References |
---|---|---|---|---|
Lung cancer | miR-107, CDK6, Rb/E2F3 pathway | BEAS-2B, A549 and H1299 | ↑ MEG8: ↑ proliferation, ↑ migration, ↑ invasion ∆ MEG8: ↓ cell progression | [7] |
miR-15a-5p, miR-15b-5p, PSAT1 | 16HBE, A549, H1299, H1975, SPC-A1, and PC-9 | ∆ MEG8: ↓ proliferation, ↓ migration, ↓ invasion | [8] | |
miR-34a and miR-203, EZH2, SNAI1 and SNAI2 | A549 and LC2/ad | MEG8 was involved in EZH2 recruitment to inhibit miR-34a and miR-203 expression. ↑ MEG8: ↑ EMT process | [9] | |
Pancreatic cancer | miR-34a and miR-203, EZH2, SNAI1 and SNAI2 | Panc1 | MEG8 was involved in EZH2 recruitment to inhibit miR-34a and miR-203 expression. ↑ MEG8: ↑ EMT process | |
Hemangioma | miR203, Notch signaling pathway | HemECs | ∆ MEG8: ↓ proliferation, ↓ migration, ↑ apoptosis | [10] |
miR-497-5p, NOTCH2 | HemECs | ∆ MEG8: ↓ proliferation, ↑ ferroptosis | [21] | |
Hepatocellular carcinoma | miR-367-3p, 14-3-3ζ, TGFβR1, TGFβ signaling | Human LO2 hepatocytes and HepG2, Huh7, HCCLM3, and HMCC-97 H HCC | ∆ MEG8: ↓ proliferation, ↓ migration, ↓ invasion | [11] |
Bone-invasive pituitary adenomas | miR-454-3p, TNF-α | 293T and RAW264.7 | ↑ MEG8: ↑ promoting RAW264.7 cells to destroy bone | [12] |
Wilms’ tumor | miR-23a-3p, CRK | WT cells | ∆ MEG8: ↓ viability, ↓ migration, ↓ invasion | [13] |
Diabetic nephropathy | miR-770-5p | CIHP-1 | ↑ MEG8: ↑ glucose-mediated apoptosis, ↑ miR-770-5p expression by reducing the methylation of miR-770-5p | [14] |
Atherosclerosis | miR-181a, PPARα | VSMCs | ↑ MEG8: ↓ VSMC proliferation, ↓ migration, ↑ apoptosis | [15] |
Ischemic stroke | miR-130a-5p, VEGFA | OGD-treated BMECs | ∆ MEG8: ↓ viability, ↓ migration, ↓ angiogenesis | [16] |
Trophoblast dysfunction and abortion |  | HTR-8/SVneo cell line from early villous trophoblasts (EVTs) | ↑ MEG8: ↓ proliferation of trophoblast, ↓ invasion | [17] |
Henoch-Schonlein purpura | miR-181a-5p, SHP2, | RMDMs from HSP rats | ↑ MEG8: ↑ M1 polarization, ↓ JAK2/STAT3 pathway | [18] |
Osteoarthritis | PI3K/AKT signaling pathway | IL-1β-treated C28/I2 cells | ∆ MEG8: ↓ proliferation, ↓ activation of the PI3K/AKT signaling pathway, ↑ apoptosis, ↑ inflammatory response | [19] |